Thomas Carl Krivak MD
Gynecologic Oncology
Assistant Professor, Ob/Gyn & Reproductive Science, University of Pittsburgh School of Medicine
Join to view full profile
4815 Liberty AveSte GR30Pittsburgh, PA 15224
Phone+1 412-578-1116
Fax+1 412-578-1116
Dr. Krivak is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
David Grant Medical CenterResidency, Obstetrics and Gynecology, 1994 - 1998
Ohio State University College of MedicineClass of 1994
Certifications & Licensure
CA State Medical License 1997 - Present
PA State Medical License 2005 - 2026
WV State Medical License 2014 - 2016
DC State Medical License 2001 - 2006
American Board of Obstetrics and Gynecology Obstetrics & Gynecology- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013, 2016-2017
- CMS Meaningful Use Stage 1 Certification dbMotion, dbMotion Inc., 2013, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2013, 2016-2017
Clinical Trials
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
- Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer
- Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
Publications & Presentations
PubMed
- 2 citationsLongitudinal methylated ctDNA increases predict immunotherapy progression across solid tumors.Muhammad Anees, Patrick L Wagner, Ashten Omstead, Erin Grayhack, Christopher Sherry
The Journal of Liquid Biopsy. 2026-09-01 - Immune checkpoint inhibition in ovarian cancer: Reassessing its potential.Jenna Zimmerman, Neda Dadgar, Thomas C Krivak, Sarah M Crafton, Eirwen M Miller
Gynecologic Oncology. 2026-08-01 - Exposure-Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial.Mita Kuchimanchi, Trine Lembrecht Jørgensen, Eva Hanze, Angela Jain, Oskar Alskär
Clinical Pharmacology in Drug Development. 2026-08-01
Journal Articles
- Survival Disparities in Vulvar Cancer Patients in Commission on Cancer®-Accredited FacilitiesNicole B Gaulin, Scott D Richard, Thomas C Krivak, Eirwen M Miller, Yovanni Casablanca, Gynecologic Oncology
Press Mentions
AHN West Penn First in Country to Perform Hysterectomy with New Robotic-Assisted Surgery System as Part of Investigative Clinical TrialNovember 7th, 2025- He Cured Her from Ovarian Cancer. She Thanked Him with More Than $700,000 to Help OthersJanuary 9th, 2022
Immunotherapy Could Be Game Changer in Cancer TreatmentApril 22nd, 2019
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
